TrialA Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Trial details
- Registry ID
- NCT03005327
- Phase
- Phase 2
XFOR
X4 Pharmaceuticals
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeNCT03005327 | X4 Pharmaceuticals | Phase 2 | Completed | 2022-06-16Actual |
| Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeNCT03995108 | X4 Pharmaceuticals | Phase 3 | Completed | 2025-12-23Actual |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsNCT06056297 | X4 Pharmaceuticals | Phase 3 | Recruiting | 2027-09Estimated |
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Trial details
- Registry ID
- NCT03995108
- Phase
- Phase 3
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Trial details
- Registry ID
- NCT06056297
- Phase
- Phase 3
Latest recorded trial changes
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
NCT03995108 · X4 Pharmaceuticals
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Dec 2025
+ After
23 Dec 2025
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297 · X4 Pharmaceuticals
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Annualized Infection Rate Based on Infections Adjudicated by Blinded Infection Adjudication Committee (BIAC) During the Treatment Period Measure: Number of Participants Meeting the Definition of a Positive Absolute Neutrophil Count (ANC) Response
+ After
Measure: Co-primary Endpoint: Annualized Infection Rate Based on Infections Adjudicated by Blinded Infection Adjudication Committee (BIAC) During the Treatment Period Measure: Co-primary Endpoint: Number of Participants Meeting the Definition of a Positive Absolute Neutrophil Count (ANC) Response
Planned enrollment increased by 26 participants
− Before
150 participants (planned)
+ After
176 participants (planned)
Primary completion date changed
− Before
Jul 2026
+ After
Sep 2027